Business Wire

Ecospray Chooses relayr to Revolutionize the Maritime Industry With Artificial Intelligence Powered Solutions

18.2.2021 15:54:00 EET | Business Wire | Press release

Share

Ecospray, a company specializing in the research and development of cutting-edge systems for controlling air and gas emissions in industrial applications for the Maritime industry, has chosen relayr, a leading industrial IoT company based in Berlin, to create new IoT-based desulphurization solutions, driving the sector towards an increasingly digital, efficient and environmentally sustainable future.

The Maritime Industry has been one of the latest in addressing the need to reduce its environmental impact. Now, with the introduction of IMO regulations aimed at reducing sulphur oxide emissions - which came into force in January 2020 - the industry is facing a rising pressure to comply with more stringent environmental regulations, as well as the need of containing costs and improve efficiency in an increasingly competitive and unpredictable market.

In this context, fleets can resort to various solutions, including the installation of scrubbers to remove SOx emissions, or using alternative fuels such as very-low-sulphur fuel oil (VLSFO) but with significantly higher costs compared to bunker fuel.

To meet these market challenges while aiming at developing new solutions capable of radically renewing the entire maritime transport sector, Ecospray has chosen to collaborate with relayr , a company specializing in IoT solutions oriented for business outcomes. The partnership between the two companies will allow the creation of a new generation of emission control equipment: smart scrubbers managed using artificial intelligence, a completely new solution for the market.

Ecospray, market leader in marine emission purification systems (EGCS), has always been committed to developing technological solutions for the maritime sector that can make the processes of reducing the pollutants in the gases produced by ships more efficient. The integrated technologies offered by Ecospray aim at reducing emissions and saving fuel, leading ship owners on the path towards decarbonization of the sector and encouraging the use of clean energy. Part of Carnival Group since 2013, the Italian company has continued to grow in recent years by increasingly specializing in offerings for the marine segment.

"Being part of Carnival Corporation has given us the opportunity to implement high-performance and reliable technological solutions in record time. We were enabled to gain experience across the entire fleet and unparalleled sailing experience, which has allowed us to build robust and use case specific innovations at speed," said Stefano Di Santo, CEO of Ecospray.

The new IMO-compliant devices are not only an innovation that drives an environmentally intensive industry towards a more sustainable future but also an investment that will significantly reduce equipment-running costs for shipbuilders.

The integration of relayr’s IIoT and AI offering tailored to the devices allows to guarantee constant compliance with IMO regulations for the containment of air pollution in the maritime environment. Moreover, it allows significant savings in terms of performance and maintenance through remote monitoring and advanced life cycle analysis. The ability to constantly monitor and analyze the scrubbers’ performance ensures longer equipment life and fuel savings by optimizing pumping operations while also allowing a significant reduction in operating costs.

"We are delighted to collaborate with a company like Ecospray, igniting together the digital transformation of the marine industry," says Josef Brunner, CEO of relayr. "This partnership allows us to enter a new market – bringing high added value with IIoT solutions, helping to exploit the full potential of the control systems machines, and ultimately contributing to the reduction of harmful gas emissions."

“In the maritime industry, a fleet could include hundreds of ships, so the opportunities to build smart machines on such a large scale are literally endless," commented Stefano Di Santo, CEO of Ecospray. "The partnership with relayr allows us to confidently face the challenge of bringing the best of 4.0 technologies to the naval sector. The constant motivation that this project offers us on a daily basis requires a totally different and creative approach to problem solving. I am certain of one thing: together we will never stop improving. Ecospray and relayr: disrupting innovations across the oceans."

The process of digitalization of equipment for gas emission control is only a first step towards a broader business transformation process for the Alessandria-based Ecospray. The visionary approach in collaboration with relayr ultimately envisages the adoption of the Equipment as a Service (EaaS) model. Unlike the traditional asset purchase model, EaaS is based on a pay-per-use offering, in which equipment is no longer purchased but provided in exchange for a usage fee.

Thanks to relayr's experience in implementing the EaaS model, Ecospray will be able to create even more value for its customers, diversifying its revenue streams by offering new services and emerging in the current market scenario.

About Ecospray
From research to development, Ecospray Technologies is specialized in integrated solutions for the green conversion of the maritime and land industries as well as the reduction of dependency on fossil fuels. Founded in 2005 and part of Carnival Group since 2013, Ecospray operates at global level, offering systems aimed at making industrial processes more sustainable through the purification and treatment of pollutants, from emission removal to fuel saving and water filtration. Ecospray's technological solutions leverage three distinctive factors – technology delivered as a service, analysis and use of relevant data, and finance – to facilitate access to innovation and significantly advance the energy transition towards decarbonization and the creation of clean energy.

About relayr
Relayr is the Industrial Internet of Things (IIoT) powerhouse delivering the most complete solutions for risk-free digital transformations. We unleash data insights from existing equipment, machines and production lines to improve our customers’ business outcomes. We enable industrial companies to shift from CAPEX to OPEX-based offerings on their respective markets, providing a unique combination of first-class IIoT technology and its delivery with powerful financial and insurance offerings – all from a single source trusted by hundreds of companies worldwide. With relayr, manufacturers, operators, and service companies for industrial equipment are empowered to implement fully interoperable IIoT solutions guaranteed to achieve their target business outcomes.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Ecospray
Eleonora Castiglione
Marketing & Communications Manager
castiglione@ecospray.eu

relayr
David Petrikat
Senior Vice President Marketing & Portfolio
david.petrikat@relayr.io

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 10:19:00 EEST | Press release

Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patients with unmet needs.” Pembrolizumab is a humanized monoclonal antibody that acts as an immune checkpoint inhibitor by targeting and blocking the programmed cell death protein 1 (PD-1) receptor on T cells. It is used to treat vari

IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 10:00:00 EEST | Press release

IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi

Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 10:00:00 EEST | Press release

Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European Medicines Agency (EMA) for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/DDC inhibitor-based treatment regimens. CHMP recommendation is based on data from the Phase 3 RISE-PD trial, which compared Hopledo® with immediate release levodopa/carbidopa (LD/CD) formulation in patients with Parkinson’s disease and moderate to severe motor fluctuations. In the study, Hopledo® demonstrated a significant increase in Good ON time over immediate release LD/CD with fewer daily doses and a comparable safety profile1. Hopledo® is a first-in-class, oral, modified-release formulation of LD/CD designed for the treatment of fluctuations of Parkinson’s diseas

Enhertu ® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 09:30:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across three phase 2 trials, including DESTINY-PanTumor02, DESTINY-Lung01 and DESTINY-CRC02. In DESTINY-PanTumor02, Enhertu demonstrated a confirmed objective response rate (ORR) of 52.3% (95% confidence interval [CI]: 42.6-6

Beerenberg Prevails in Patent Case Against Aspen Aerogels29.6.2026 08:00:00 EEST | Press release

The Korean Patent Court has invalidated three of Aspen Aerogels’ patents related to improved hydrophobic aerogel material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260628192007/en/ Beerenberg delivers high-end insulation solutions built for performance, reliability, and long-term value. (Photo: Beerenberg) The ruling confirms the conclusion of the Intellectual Property Trial and Appeal Board (IPTAB) that the patents did not meet the necessary requirements for patentability. Beerenberg, which specializes in high-end insulation products, welcomes the court’s decision. “We are pleased that the case has now been concluded and that any uncertainty regarding the infringement claims has been removed,” says CEO Arild Apelthun. About Beerenberg Beerenberg has delivered cost-efficient solutions to a wide range of industrial enterprises for 49 years. The company is one of the leading suppliers of maintenance and modification serv

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye